P,kinetic parameters Type of formulation/route of administration HP-SLN i.n.* HP-Sol. i.n.# HP-Sol. i.v. Brain Plasma Brain Plasma Brain Plasma Cmax(ng/mL) 329.17 ± 20.89 393.5 ± 24.63 90.13± 6.28 306.96 ± 13.47 76.95 ± 7.62 2190 ± 60.67 Tmax (h) 2 4 2 1 1 0.167 AUC0-24 h (ng∙h/mL) 2172.33 ± 60.41 2433.05 ± 18.54 623.16 ±  8.51 1460.71 ± 15.67 433.65 ± 15.46 11464.59 ± 150.45 AUC0-∞ (ng∙h/mL) 2389.17 ± 78.82 2612.31 ± 40.67 683.15 ± 30.17 1681.82 ± 32.83 500.82 ± 12.78 12017.5 ±180.87 Ke (h-1) 0.079 ± 0.0065 0.097 ± 0.003 0.077 ±  0.005 0.11 ± 0.003 0.095 ± 0.003 0.15 ± 0.007 MRT (h) 12.60 ±0.99 7.60 ± 0.32 9.17 ±   0.45 8.9 ± 0.57 10.38 ± 0.65 5.92 ±0.57 RB (%)a 349.72 ±26.13 155.32 ±11.83

Values are mean ± SD, n=6, a relative to HP sol. i.n., *�� ˂ 0.05 versus HP sol. i.n., *�� ˂ 0.05 versus HP sol. i.v., #P < 0.05 versus HP sol. i.v., P < 0.05 results are significant

Table 10: Pharmacokinetic parameters of haloperidol in Brain and Plasma after HP-SLNs i.n., HP sol. i.n. and HP sol. i.v. administration to Rats.